Accueil   Diary - News   All news Adocia initie une étude comparative BioChaperone ® Lispro

Adocia initie une étude comparative BioChaperone ® Lispro

 

Adocia initiates BioChaperone® Lispro comparative study to validate THDB insulin lispro for Phase 3 BC Lispro trials in Europe and U.S.

 

  • The purpose of the comparative study is to demonstrate safety and efficacy of BioChaperone® Lispro (BC Lispro) using Tonghua Dongbao (THDB) lispro as the drug substance.
  • In nine previous studies, BC Lispro demonstrated significant improvement compared to Humalog®, Aspart® and Fiasp®, while also proving to be safe and well tolerated.
  • Trial design approved by BfArM and FDA to enable pivotal Phase 3 trials in Europe and U.S.

 

 

Read the press release